Latest Sarepta Therapeutics News & Updates

See the latest news and media coverage for Sarepta. We track all announcements, press releases, and industry mentions in real time, all in one place.

Sarepta Therapeutics (Sarepta)

Biotechnology company developing genetic medicines for rare diseases

sarepta.com

Headquarters: Cambridge, United States
Company type: Public company
Number of employees: 1,000–1,200
Industry: Pharmaceuticals

Last updated November 6

Latest news about Sarepta Therapeutics (Sarepta)

In short: Sarepta said it would not resume ENVISION enrollment and raised the low end of 2026 revenue guidance.

Company announcements

November 5 Sarepta

Sarepta reports third quarter 2026 financial results

Net product revenue totaled $323.8 million, with GAAP operating loss of $9.0 million and non-GAAP operating income of $22.9 million; it raises the low end of 2026 revenue guidance.

August 5 Sarepta

Sarepta reports Q2 2026 financial results

Net product revenue totaled $328.7 million. The company achieved operating profitability and announced new CEO Michael Severino, M.D., alongside narrowed FY 2026 guidance.

July 31 Sarepta

Sarepta reports first half 2026 financial results and strategic updates

Revenue declined to $1.13 billion in the first half of 2026 from $1.35 billion in the prior year period due to Elevidys shipment suspensions.

July 27 Sarepta

Sarepta appoints Michael Severino as CEO

Severino joins the Board succeeding Doug Ingram who retires after guiding Sarepta through significant growth and therapeutic approvals.

Media coverage

November 6 Endpoints News

Sarepta quits enrolling for confirmatory Phase 3 trial of Elevidys

Sarepta won’t resume enrollment in Elevidys’ Phase 3 ENVISION trial, betting on a new immunosuppression cohort to return the gene therapy to older boys.

November 6 BioSpace

Sarepta CEO touts clinical execution amid DMD competition

New CEO Michael Severino says better trial design and site selection can restore Sarepta’s leadership in Duchenne muscular dystrophy as rivals near approval.

November 5 MarketScreener

Sarepta Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026

Sarepta Therapeutics, Inc. reported earnings results for the third quarter and nine months ended September 30, 2026. For the third quarter, the company reported revenue...

November 5 BioSpace

Sarepta Therapeutics Announces Third Quarter 2026 Financial Results and Recent Corporate Developments - BioSpace

Sarepta is actively preparing for Phase 3 development in both programs, including beginning manufacturing of clinical supply. The Company is preparing for both accelerated and...

Never miss news about Sarepta

Track Sarepta and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Sarepta competitors & trending companies

Browse news for competitors to Sarepta and other trending companies.